CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice

Journal of Alzheimer's Disease

Volumn 30, Issue 2, 2012, Pages 439-459

  Aso, Ester ^a   Palomer, Ernest ^b   Juvés, Salvador ^a   Maldonado, Rafael ^b   Muoz, Francisco J ^b   Ferrer, Isidro ^a,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; astrogliosis; cannabinoid receptor; GSK3 ; neuroprotection; transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR AGONIST; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL-2-CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NEUROPROTECTIVE AGENT; PRESENILIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CULTURE; COGNITIVE DEFECT; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; ALZHEIMER DISEASE; ANIMAL; BRAIN CORTEX; COGNITION; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; GLIOSIS; HIPPOCAMPUS; METABOLISM; PHYSIOLOGY; PREGNANCY; PRIMARY CELL CULTURE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ARACHIDONIC ACIDS; ASTROCYTES; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; GLIOSIS; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MALE; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PREGNANCY; PRESENILIN-1; PRIMARY CELL CULTURE; RECEPTOR, CANNABINOID, CB1;

EID: 84861513395     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111862     Document Type: Article

References (56)

1. Alzheimer's Association (2010) Alzheimer'sdisease facts and figures. Alzheimers Dement 6, 9-14.
2. Koppel J, Davies P (2008) Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis 15, 495-504.
3. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884. (Pubitemid 37351427)
4. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11, 563-583.
5. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 1017-1030.
6. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296, 678-682.
7. Fride E (2005) Endocannabinoids in the central nervous system: From neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 4, 633-642. (Pubitemid 41782625)
8. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against exci-totoxicity. Science 302, 84-88. (Pubitemid 37210691)
9. Aguado T, Romero E, Monory K, Palazuelos J, Sendtner M, Marsicano G, Lutz B, Guzmán M, Galve-Roperh I (2007) The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem 282, 23892-23898. (Pubitemid 47328042)
10. Núñez E, Benito C, Pazos MR, Barbachano A, Fajardo O, González S, Tolón RM, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 53, 208-213. (Pubitemid 39045539)
11. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J (2008) Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153, 277-285.
12. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M (2007) Cannabinoid CB2 receptor: A new target for controlling neural cell survival? Trends Pharmacol Sci 28, 39-45. (Pubitemid 46038536)
13. Raḿirez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913. (Pubitemid 40289395)
14. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151, 1272-1279. (Pubitemid 47255904)
15. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, Di Marzo V, Steardo L (2007) Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther322, 1144-1152. (Pubitemid 47295817)
16. Mart́in-Moreno AM, Reigada D, Raḿirez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimers' disease. Mol Pharmacol 79, 964-973.
17. Campbell VA, Gowran A (2007) Alzheimer's disease; taking the edge off with cannabinoids? Br J Pharmacol 152, 655-662. (Pubitemid 350034982)
18. Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA (2010) Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 285, 38543-38554.
19. Chen X, Zhang J, Chen C (2011) Endocannabinoid 2-arachidonoylglycerol protects neurons against fj-amyloid insults. Neuroscience 178, 159-168.
20. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289, 1427-1433. (Pubitemid 29246674)
21. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945. (Pubitemid 27471397)
22. Aso E, Lomoio S, Lopez-Gonzalez I, Joda L, Carmona M, Fernandez-Yagüe N, Moreno J, Juves S, Pujol A, Pamplona R, Portero-Otin M, Mart́in V, D́iaz M, Ferrer I (2011) Amyloid generation and dysfunctional immuno-proteasome activation with disease progression in animal model of familial Alzheimer disease. Brain Pathol, doi: 10.1111/j.1750-3639. 2011.00560.x.
23. Puig B, Gomez-Isla T, Ribe E, Cuadrado M, Torrejon-Escribano B, Dalfo E, Ferrer I (2004) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding beta plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30, 491-502. (Pubitemid 39423036)
24. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12, 1152-1158.
25. Quintanilla RA, Muñoz FJ, Metcalfe MJ, Hitschfeld M, Olivares G, Godoy JA, Inestrosa NC (2005) Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J Biol Chem 280, 11615-11625. (Pubitemid 40418475)
26. Ozaita A, Puighermanal E, Maldonado R (2007) Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102, 1105-1114. (Pubitemid 47174245)
27. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J (2010) GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol 223, 322-325.
28. Hanger DP, Noble W (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011, 352805.
29. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herken-ham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63, 637-652. (Pubitemid 24360219)
30. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, Wong PT, Chen CP, Lai MK (2010) Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem Int 57, 985-989.
31. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, Kofalvi A, Mart́in-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobagyi T, de Ceballos ML, Harkany T (2011) Molecular reorganization of endo-cannabinoid signalling in Alzheimer's disease. Brain 134, 1041-1060.
32. Kalifa S, Polston EK, Allard JS, Manaye KF (2011) Distribution patterns of cannabinoid CB1 cannabinoid receptors in the hippocampus of APPswe/PS1AE9 double transgenic mice. Brain Res 1376, 94-100.
33. Bilkei-Gorzo A, Racz I, Valverde O, Otto M, Michel K, Sastre M, Zimmer A (2005) Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci USA 102, 15670-15675. (Pubitemid 41528114)
34. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V (2006) Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63, 1410-1424. (Pubitemid 43939021)
35. Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W (2010) Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr Alzheimer Res 7, 255-261.
36. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, Fernandez-Ruiz JJ, Ramos JA (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30, 298-308. (Pubitemid 28447177)
37. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005) Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol Biochem Behav 81, 300-318. (Pubitemid 40807129)
38. Riedel G, Davies SN (2005) Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 168, 445-477.
39. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernandez-Ruiz J (2003) Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14, 813-816. (Pubitemid 36667917)
40. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 19, 96-107. (Pubitemid 40544727)
41. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, D́iaz-Hernandez M, Ruiz C, Sendtner M, Lucas JJ, de Yebenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Gines S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119-136.
42. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65, 391-426. (Pubitemid 32781670)
43. Rockenstein E, Torrance M, Adame A, Mante M, Baron P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phospho-rylation. J Neurosci 27, 1981-1991.
44. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439. (Pubitemid 351316776)
45. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7, 656-664.
46. Esposito G, De Filippis D, Steardo L, Scuderi C, Savani C, Cuomo V, Iuvone T (2006) CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphoryla-tion in co-cultured neurons. Neurosci Lett 404, 342-346. (Pubitemid 44108437)
47. Sánchez C, Galve-Roperh I, Rueda D, Guzmán M (1998) Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54, 834-843. (Pubitemid 28523175)
48. Blázquez C, Sánchez C, Daza A, Galve-Roperh I, Guzmán M (1999) The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. J Neurochem 72, 1759-1768. (Pubitemid 29140854)
49. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23, 6470-6474. (Pubitemid 36909872)
50. Stella N (2004) Cannabinoid signaling in glial cells. Glia 48, 267-277. (Pubitemid 39578029)
51. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK (2005) Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219. (Pubitemid 40188500)
52. Rodŕiguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localizationoftheCB1 receptorinmu-opioid receptorpatches of the rat caudate putamen nucleus. J Neurosci 21, 823-833. (Pubitemid 32163123)
53. Salio C, Doly S, Fischer J, Franzoni MF, Conrath M (2002) Neuronal and astrocytic localization ofCB1 in the dorsal horn of the rat spinal cord. Neurosci Lett 329, 13-16.
54. Navarrete M, Araque A (2008) Endocannabinoids mediate neuron-astrocyte communication. Neuron 57, 883-893. (Pubitemid 351400634)
55. Navarrete M, Araque A (2010) Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126.
56. Racz I, Nadal X, Alferink J, Baños JE, Rehnelt J, Mart́in M, Pintado B, Gutierrez-Adán A, Sanguino E, Bellora N, Man-zanares J, Zimmer A, Maldonado R (2008) Interferon-gamma is a critical modulator of CB (2) cannabinoid receptor signaling during neuropathic pain. J Neurosci 28, 12136-12145.